Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Dermatology

Systemic Risk and Rare Associations

At a Glance

For most patients, primary cutaneous amyloidosis (PCA) is strictly a skin condition that does not affect life expectancy. However, rare subtypes like nodular amyloidosis require regular blood and urine screening to rule out systemic diseases like AL amyloidosis and Sjögren's syndrome.

For the vast majority of patients with Primary Cutaneous Amyloidosis (PCA), the condition is strictly a skin issue. The overall prognosis is excellent, and it does not shorten life expectancy [1][2]. However, medical science has identified a few extremely rare links between certain PCA subtypes and other health conditions [3][4]. Understanding these is not meant to cause panic, but to ensure your care team knows when to perform simple screenings [5][6].

Macular and Lichen Amyloidosis: Rare Genetic Links

Almost all cases of macular and lichen amyloidosis are caused by friction or localized factors [7][8]. However, a very small percentage (primarily those with a strong family history) are linked to other conditions:

  • MEN2A (Multiple Endocrine Neoplasia Type 2A): This is an incredibly rare inherited genetic syndrome that can involve tumors of the thyroid and adrenal glands [3]. In a very small subset of families with MEN2A, lichen amyloidosis appearing specifically on the upper back is one of the first visible signs [3][9].
    • Do you need to panic? No. If you have lichen amyloidosis on your shins, or if you have no family history of thyroid/adrenal issues, routine screening for this is generally not necessary. If you do have lesions localized on the upper back and a family history of thyroid tumors, simply ask your doctor if a genetic screening (for the RET gene) is appropriate [3].

Nodular Amyloidosis: The Need for Vigilance

The nodular subtype requires a higher level of monitoring compared to the other forms [10][6]. Because it is made from the same “light-chain” proteins seen in serious systemic diseases, doctors must work to prove it is localized only to your skin [10][5].

  • Systemic AL Amyloidosis: A serious condition where amyloid builds up in internal organs [5][11]. While most nodular PCA cases stay in the skin, there is a risk they could be an early sign of systemic disease or progress over many years [12][6].
  • Sjögren’s Syndrome: There is a recognized link between nodular amyloidosis and Sjögren’s, an autoimmune condition causing extreme dry eyes and dry mouth [4][12].

Screening for Nodular Amyloidosis

If you have the nodular subtype, your doctor will likely recommend a “systemic work-up” at diagnosis and periodically thereafter [5][4]. This typically includes:

  1. Serum and Urine Protein Electrophoresis (SPEP/UPEP): Blood and urine tests to look for abnormal “monoclonal” proteins [12][13].
  2. Serum Free Light Chain (FLC) Assay: A blood test to check the levels of the specific proteins that form nodular amyloid [14][15].

Monitoring is simply a “safety net” to catch potential changes early [12].

Common questions in this guide

Does primary cutaneous amyloidosis affect my internal organs?
For the vast majority of patients, primary cutaneous amyloidosis is strictly a skin condition. It generally does not involve internal organs or shorten your life expectancy.
Why do I need blood tests for nodular amyloidosis?
Nodular amyloidosis is made of light-chain proteins, which can sometimes be linked to systemic diseases. Doctors use blood and urine tests, like SPEP and free light chain assays, to confirm the abnormal proteins are only in your skin and not in your internal organs.
Is lichen amyloidosis a sign of an underlying genetic disease?
In extremely rare cases, lichen amyloidosis appearing on the upper back can be an early sign of MEN2A, an inherited genetic syndrome. If you have this specific type of rash and a family history of thyroid tumors, your doctor may recommend genetic screening.
What is the link between Sjögren's syndrome and amyloidosis?
There is a recognized medical link between the nodular subtype of primary cutaneous amyloidosis and Sjögren's syndrome. Sjögren's is an autoimmune condition that causes extreme dry eyes and dry mouth.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my diagnosis and family history, do I need to be screened for any underlying genetic syndromes like MEN2A?
  2. 2.For my nodular amyloidosis, what specific blood and urine tests do I need to ensure my internal organs are not affected?
  3. 3.How often should I have follow-up testing (like SPEP or light chain assays) to monitor for systemic changes?
  4. 4.Do I need bloodwork to check for systemic proteins based on my specific symptoms?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Localized light chain amyloidosis: A self-limited plasmacytic B-cell lymphoproliferative disorder.

    Martínez JC, Lichtman EI

    Frontiers in oncology 2022; (12()):1002253 doi:10.3389/fonc.2022.1002253.

    PMID: 36457485
  2. 2

    Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study.

    Mahmood S, Bridoux F, Venner CP, et al.

    The Lancet. Haematology 2015; (2(6)):e241-50.

    PMID: 26688234
  3. 3

    Endocrine Perspective of Cutaneous Lichen Amyloidosis: RET-C634 Pathogenic Variant in Multiple Endocrine Neoplasia Type 2.

    Florescu AF, Sima OC, Nistor C, et al.

    Clinics and practice 2024; (14(6)):2284-2299 doi:10.3390/clinpract14060179.

    PMID: 39585007
  4. 4

    Localized Cutaneous Nodular Amyloidosis: A Specific Cutaneous Manifestation of Sjögren's Syndrome.

    Llamas-Molina JM, Velasco-Amador JP, De la Torre-Gomar FJ, et al.

    International journal of molecular sciences 2023; (24(8)) doi:10.3390/ijms24087378.

    PMID: 37108553
  5. 5

    [Endogenous skin overloads].

    Ortonne N

    Annales de pathologie 2024; (44(6)):476-485 doi:10.1016/j.annpat.2024.09.006.

    PMID: 39368935
  6. 6

    A suspicious nodule in a toe web space.

    Gilbert G, Wiggins J, Biswas A, Gupta G

    Clinical and experimental dermatology 2025; (50(8)):1704-1706 doi:10.1093/ced/llaf113.

    PMID: 40059631
  7. 7

    Tofacitinib for the treatment of primary cutaneous amyloidosis: A case report.

    Chen J, Yang B

    Dermatologic therapy 2022; (35(4)):e15312 doi:10.1111/dth.15312.

    PMID: 35001465
  8. 8

    Pathophysiology of pruritus in primary localized cutaneous amyloidosis.

    Tey HL, Cao T, Nattkemper LA, et al.

    The British journal of dermatology 2016; (174(6)):1345-50 doi:10.1111/bjd.14391.

    PMID: 26748444
  9. 9

    Metastatic pheochromocytoma in MEN 2A: A rare association.

    Pal R, Rastogi A, Kumar S, Bhansali A

    BMJ case reports 2018; (2018()) doi:10.1136/bcr-2017-222758.

    PMID: 29592980
  10. 10

    Nodular Cutaneous Amyloidosis on the Nose Confirmed Using Electron Microscopy: A Case Report.

    Choi GW, Kim DH

    Annals of dermatology 2023; (35(Suppl 2)):S376-S377 doi:10.5021/ad.22.075.

    PMID: 38061751
  11. 11

    Subcutaneous scalp nodule as the presenting symptom of systemic light-chain amyloidosis.

    Tadros J, Goodman S, Tkaczyk ER

    Dermatology practical & conceptual 2018; (8(3)):184-187 doi:10.5826/dpc.0803a07.

    PMID: 30116661
  12. 12

    More Than Just a Plaque: A Diagnostic Challenge in a Case of Suspected Cutaneous Localized Nodular Amyloidosis.

    Shah S, Shrestha J

    Clinical case reports 2025; (13(11)):e71514 doi:10.1002/ccr3.71514.

    PMID: 41280259
  13. 13

    Immunoglobulin heavy/light chain assay in the diagnosis, monitoring and follow-up of renal AL amyloidosis patients at different disease stages.

    Wang Y, Liu F, Liu Y, et al.

    Annals of hematology 2025; (104(4)):2287-2295 doi:10.1007/s00277-025-06345-7.

    PMID: 40202538
  14. 14

    Free light chain testing for the diagnosis, monitoring and prognostication of AL amyloidosis.

    Mollee P, Merlini G

    Clinical chemistry and laboratory medicine 2016; (54(6)):921-7.

    PMID: 26812792
  15. 15

    A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis.

    Sharpley FA, Manwani R, Mahmood S, et al.

    Blood cancer journal 2019; (9(2)):16 doi:10.1038/s41408-019-0180-1.

    PMID: 30718462

This page discusses rare systemic risks associated with primary cutaneous amyloidosis for educational purposes only. Always consult your dermatologist or primary care provider to determine if screening tests are necessary for your specific subtype.

Get notified when new evidence is published on Primary cutaneous amyloidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.